Isodiol International Inc. (
CSE: C.ISOL,
OTC: ISOLF,
Forum) said Monday it has entered into a definitive agreement to acquire 100% of Canadian National Pharma Group Inc., a pharmaceutical manufacturing company.
Isodiol previously announced on December 6, 2017, the agreement to acquire an initial stake, representing 25% equity of CN Pharma.
The company is now pleased to purchase the remaining 75% equity and is excited to establish CN Pharma as a wholly-owned subsidiary.
More information can be found
here.
Isodiol is a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products.
Isodiol was in the news recently when the company announced fiscal 2018 Q2 revenues of its wholly-owned subsidiary ISO International LLC.
FULL DISCLOSURE: Isodiol International Inc. is a paid client of Stockhouse Publishing.